Arsenic and its combinations in cancer therapeutics

Therapeutic Delivery

Volumn 2, Issue 6, 2011, Pages 793-806

  Prajapati, Vandana ^a   Kale, Raosaheb K ^a,b   Singh, Rana P ^a,b  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b CENTRAL UNIVERSITY OF GUJARAT   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARSANILIC ACID; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; ARSPHENAMINE; ASCORBIC ACID; AZACITIDINE; BORTEZOMIB; CYTARABINE; DARINAPARSIN; DAUNORUBICIN; DEXAMETHASONE; EMODIN; ERUCIN; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; GENISTEIN; IDARUBICIN; MELARSONYL POTASSIUM; MELARSOPROL; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NETOGLITAZONE; PARTHENOLIDE; RETINOIC ACID; SULFORAPHANE; SULINDAC; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTINEOPLASTIC ACTIVITY; ARSENIC POISONING; ASTHMA; BANCROFTIAN FILARIASIS; BRAIN DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENICITY; CELL MEMBRANE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPLEX FORMATION; DISEASE FREE SURVIVAL; DNA ADDUCT; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; ECZEMA; EVENT FREE SURVIVAL; FILARIASIS; GASTRIC ULCER BLEEDING; GRAND MAL SEIZURE; HEART ARRHYTHMIA; HEARTBURN; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERTENSION; LEUKEMIA; LEUKEMIA REMISSION; LEUKOCYTOSIS; LIVER TOXICITY; LYMPHATIC LEUKEMIA; MAINTENANCE THERAPY; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; MYELOMA; NEUROTOXICITY; NONHUMAN; ONCHOCERCIASIS; OVERALL SURVIVAL; OXIDATIVE STRESS; PANCREAS CANCER; PARASITOSIS; PEMPHIGUS; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; PSORIASIS; QT PROLONGATION; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; SKIN CANCER; SOLID TUMOR; SURVIVAL RATE; SYPHILIS; T CELL LEUKEMIA; TRYPANOSOMIASIS; WATER CONTAMINATION;

EID: 79960241290     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.51     Document Type: Review

References (95)

1. Chowdhury UK, Biswas BK, Chowdhury TR et al. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ. Health Perspect. 108(5), 393-397 (2000) (Pubitemid 30421015)
2. National Research Council. Arsenic in Drinking Water. National Academy Press, Washington, DC, USA, 7 (1999)
3. National Research Council. Arsenic in Drinking Water. National Academy Press, Washington, DC, USA 14 (2001)
4. Ramrez-Sols A, Mukopadhyay R, Rosen BP, Stemmler TL. Experimental and theoretical characterization of arsenite in water: insights into the coordination environment of As-O. Inorg. Chem. 43(9), 2954-2959 (2004)
5. Liu Z, Shen J, Carbrey JM, Mukhopadhyay R, Agre P, Rosen BP. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl Acad. Sci. USA 99(9), 6053-6058 (2002) (Pubitemid 34493263)
6. Carbrey JM, Song L, Zhou Y et al. Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice. Proc. Natl Acad. Sci. USA 106(37), 15956-15960 (2009)
7. Benbrahim-Tallaa L, Webber MM, Waalkes MP. Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ. Health Perspect. 115(2), 243-247 (2007)
8. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 15(22), 6269-6279 (1996) (Pubitemid 26397900)
9. Suzuki N, Naranmandura H, Hirano S, Suzuki KT. Theoretical calculations and reaction analysis on the interaction of pentavalent thioarsenicals with biorelevant thiol compounds. Chem. Res. Toxicol. 21(2), 550-553 (2008)
10. Raab A, Wright SH, Jaspars M, Meharg AA, Feldmann J. Pentavalent arsenic can bind to biomolecules. Angew. Chem. Int. Ed. Engl. 46(15), 2594-2597 (2007) (Pubitemid 46973540)
11. Bertolero E, Pozzi G, Sabbioni E, Saffiotti U. Cellular uptake and metabolic reduction of pentavalent and metabolic reduction of pentavalent to trivalent arsenic as determinants of cytotoxicity and morphological transformation. Carcinogenesis 8(6), 803-808 (1987) (Pubitemid 17122533)
12. Dopp E, Hartmann LM, Florea AM et al. Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicol. Appl. Pharmacol. 201(2), 156-165 (2004) (Pubitemid 39487163)
13. Dopp E, Hartmann LM, von Recklinghausen U et al. Forced uptake of trivalent and pentavalent methylated and inorganic arsenic and its cyto-/genotoxicity in fibroblasts and hepatoma cells. Toxicol. Sci. 87(1), 46-56 (2005) (Pubitemid 41222657)
14. Ahmad S, Kitchin KT, Cullen WR. Arsenic species that cause release of iron from ferritin and generation of activated oxygen. Arch. Biochem. Biophys. 382(2), 195-202 (2000)
15. Zhang TL, Gao YX, Lu JF, Wang K. Arsenite, arsenate and vanadate affect human erythrocyte membrane. J. Inorg. Biochem. 79(1-4), 195-203 (2000) (Pubitemid 30628731)
16. Barchowsky A, Klei LR, Dudek EJ, Swartz HM, James PE. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med. 27(11-12), 1405-1412 (1999) (Pubitemid 30001503)
17. Pi J, Horiguchi S, Sun Y et al. A potential mechanism for the impairment of nitric oxide formation caused by prolonged oral exposure to arsenate in rabbits. Free Radic. Biol. Med. 35(1), 102-113 (2003) (Pubitemid 36782341)
18. Rin K, Kawaguchi K, Yamanaka K, Tezuka M, Oku N, Okada S. DNA-strand breaks induced by dimethylarsinic acid, a metabolite of inorganic arsenics, are strongly enhanced by superoxide anion radicals. Biol. Pharm. Bull. 18(1), 45-48 (1995)
19. Yamanaka K, Takabayashi F, Mizoi M, An Y, Hasegawa A, Okada S. Oral exposure of dimethylarsinic acid, a main metabolite of inorganic arsenics, in mice leads to an increase in 8-Oxo-2′-deoxyguanosine level, specifically in the target organs for arsenic carcinogenesis. Biochem. Biophys. Res. Commun. 287(1), 66-70 (2001) (Pubitemid 32916118)
20. Gurr JR, Liu F, Lynn S, Jan KY. Calcium-dependent nitric oxide production is involved in arsenite-induced micronuclei. Mutat. Res. 416(3), 137-148 (1998) (Pubitemid 28404647)
21. Schwerdtle T, Walter I, Mackiw I, Hartwig A. Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis 24(5), 967-974 (2003) (Pubitemid 36748914)
22. Bode AM, Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 42(1), 5-24 (2002) (Pubitemid 34229146)
23. Straub AC, Klei LR, Stolz DB, Barchowsky A. Arsenic requires sphingosine-1-phosphate type 1 receptors to induce angiogenic genes and endothelial cell remodeling. Am. J. Pathol. 174(5), 1949-1958 (2009)
24. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenicinduces oxidant stress and NF-kB activation in cultured aortic endothelial cells. Free Radic. Biol. Med. 21(6), 783-790 (1996) (Pubitemid 26365274)
25. Corsini E, Asti L, Viviani B, Marinovich M, Galli CL. Sodium arsenate induces overproduction of interleukin-1α in murine keratinocytes: Role of mitochondria. J. Invest. Dermatol. 113(5), 760-765 (1999)
26. Kaltreider RC, Pesce CA, Ihnat MA, Lariviere JP, Hamilton JW. Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding. Mol. Carcinog. 25(3), 219-229 (1999) (Pubitemid 29319287)
27. Wijeweera JB, Gandolfi AJ, Parrish A, Lantz RC. Sodium arsenite enhances AP-1 and NFkB DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol. Sci. 61(2), 283-294 (2001) (Pubitemid 32499396)
28. Germolec DR, Yoshida T, Gaido K et al. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol. 141(1), 308-318 (1996) (Pubitemid 26414378)
29. Qian Y, Castranova V, Shi X. New perspectives in arsenic-induced cell signal transduction. J. Inorg. Biochem. 96(2-3), 271-278 (2003) (Pubitemid 36900365)
30. Huang C, Bode AM, Chen NY et al. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res. 21(1A), 261-267 (2001)
31. Huang C, Ma WY, Li J, Goranson A, Dong Z. Requirement of ERK, but not JNK, for arsenite-induced cell transformation. J. Biol. Chem. 274(21), 14595-14601 (1999)
32. Kharbanda S, Saxena S, Yoshida K et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J. Biol. Chem. 275(25), 322-327 (2000) (Pubitemid 30038988)
33. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. 19(12), 8469-8478 (1999) (Pubitemid 30414041)
34. Qu W, Bortner CD, Sakurai T, Hobson MJ, Waalkes MP. Acquisition of apoptotic resistance in arsenic-induced malignant transformation: role of the JNK signal transduction pathway. Carcinogenesis 23(1), 151-159 (2002) (Pubitemid 34213564)
35. Wang XJ, Sun Z, Chen W, Li Y, Villeneuve NF, Zhang DD. Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction. Toxicol. Appl. Pharmacol. 230(3), 383-389 (2008)
36. IARC. Some metals and metallic compounds. In: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans (Volume 23). International Agency for Research on Cancer, Lyon, France, 438 (1980)
37. IARC. Overall evaluations of carcinogenicity. In: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans (Supplement 7). International Agency for Research on Cancer, Lyon, France, 440 (1987)
38. Wu MM, Chiou HY, Wang TW et al. Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ. Health Perspect. 109(10), 1011-1107 (2001)
39. Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 89(9), 3487-3488 (1997)
40. Cutler EG, Bradford EH. Action of iron, cod-liver oil, and arsenic on the globular richness of the blood. Am. J. Med. Sci. 75, 74-84 (1878)
41. Aronson SM. Arsenic and old myths. RI Med. 77(7), 233-234 (1994)
42. Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS. The composition of Ehrlichs salvarsan: resolution of a century-old debate. Angew. Chem. Int. Ed. Engl. 44(6), 941-944 (2005) (Pubitemid 40239026)
43. Friedheim EA. Mel B in the treatment of human trypanosomiasis. Am. J. Trop. Med. Hyg. 29(2), 173-180 (1949)
44. Bouteille B, Oukem O, Bisser S, Dumas M. Treatment perspectives for human African trypanosomiasis. Fundam. Clin. Pharmacol. 17(2), 171-181 (2003) (Pubitemid 36513208)
45. Wang G, Xiao B, Huang Y. Epidemiological studies on endemic fluorosis and arsenism in Xinjiang. Zhonghua Yu Fang Yi Xue Za Zhi 29(1), 30-33 (1995)
46. Wang ZG, Rivi R, Delva L et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARa independent manner. Blood 92(5), 1497-1504 (1998) (Pubitemid 28406851)
47. König A, Wrazel L, Warrell RP Jr et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 90(2), 562-570 (1997) (Pubitemid 27299095)
48. Bajenova O, Tang B, Pearse R, Feinman R, Childs BH, Michaeli J. RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis 9(5), 561-571 (2004) (Pubitemid 39158632)
49. Rousselot P, Larghero J, Labaume S et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur. J. Haematol. 72(3), 166-171 (2004) (Pubitemid 38250793)
50. Rousselot P, Larghero J, Arnulf B et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 18(9), 1518-1521 (2004) (Pubitemid 39264075)
51. Soignet SL, Tong WP, Hirschfeld S, Warrell RP Jr. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother. Pharmacol. 44(5), 417-421 (1999) (Pubitemid 29455588)
52. Mann KK, Wallner B, Lossos IS, Miller WH Jr. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin. Investig. Drugs 18(11), 1727-1734 (2009)
53. Lu DP, Qiu JY, Jiang B et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99(9), 3136-3143 (2002) (Pubitemid 34525290)
54. Du YH, Ho PC. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. Cancer Chemother. Pharmacol. 47(6), 481-490 (2001) (Pubitemid 32477294)
55. 6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells. Oncol. Rep. 12(3), 573-580 (2004)
56. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann. Oncol. 17(1), 131-134 (2006) (Pubitemid 43033852)
57. Mathews V, George B, Lakshmi KM et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107(7), 2627-2632 (2006)
58. Maeda H, Hori S, Ohizumi H et al. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and l-buthionine-sulfoximine. Cell Death Differ. 11(7), 737-746 (2004) (Pubitemid 39023120)
59. Jin HO, Yoon SI, Seo SK et al. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down regulation of survivin. Biochem. Pharmacol. 72(10), 1228-1236 (2006)
60. Wang W, Adachi M, Zhang R, Zhou J, Zhu D. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas 38(4), e114-e123 (2009)
61. Chowdhury R, Chowdhury S, Roychoudhury P, Mandal C, Chaudhuri K. Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. Apoptosis 14(1), 108-123 (2009)
62. Lee PC, Kakadiya R, Su TL, Lee TC. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. Neoplasia 12(5), 376-387 (2010)
63. Subbarayan PR, Lee K, Ardalan B. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 in vitro re-sensitizing cells to 5-FU. Anticancer Res. 30(4), 1157-1162 (2010)
64. Kumagai T, Ikezoe T, Gui D et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-g ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin. Cancer Res. 10(4), 1508-1520 (2004) (Pubitemid 38365247)
65. Chen G, Wang Y, Huang H et al. Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur. J. Haematol. 82(3), 176-183 (2009)
66. Campbell RA, Sanchez E, Steinberg JA et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br. J. Haematol. 138(4), 467-478 (2007) (Pubitemid 47063028)
67. Diaz Z, Laurenzana A, Mann KK, Bismar TA, Schipper HM, Miller WH Jr. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia 21(10), 2117-2127 (2007) (Pubitemid 47430453)
68. Zhang QY, Mao JH, Liu P et al. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc. Natl Acad. Sci. USA 106(9), 3378-3383 (2009)
69. Chung WH, Sung BH, Kim SS, Rhim H, Kuh HJ. Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int. J. Oncol. 34(6), 1669-1679 (2009)
70. Yang J, Li H, Chen YY et al. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic. Biol. Med. 37(12), 2027-2041 (2004) (Pubitemid 39491322)
71. Ma Y, Wang J, Liu L et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kB. Cancer Lett. 301(1), 75-84 (2011)
72. Jiang H, Ma Y, Chen X et al. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cancer Sci. 101(4), 975-983 (2010)
73. Biswas S, Zhao X, Mone AP et al. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leuk. Res. 34(7), 925-931 (2010)
74. Doudican NA, Bowling B, Orlow SJ. Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk. Res. 34(2), 229-234 (2010)
75. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 101(15), 5328-5335 (2004) (Pubitemid 38481160)
76. Hermine O, Dombret H, Poupon J et al. Phase II trial of arsenic trioxide and a interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol. J. 5(2), 130-134 (2004) (Pubitemid 38519262)
77. Aribi A, Kantarjian HM, Estey EH et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109(7), 1355-1359 (2007) (Pubitemid 46466562)
78. Liu YJ, Wu DP, Liang JY et al. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Med. Oncol. DOI: 10.1007/s12032-010-9733-7 (2010) (Epub ahead of print)
79. Dai CW, Zhang GS, Shen JK et al. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol. 121(1), 1-8 (2009)
80. Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol. 27(4), 504-510 (2009)
81. Powell BL, Moser B, Stock W et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116(19), 3751-3757 (2010)
82. Gore SD, Gojo I, Sekeres MA et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J. Clin. Oncol. 28(6), 1047-1053 (2010)
83. Leu L, Mohassel L. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am. J. Health Syst. Pharm. 66(21), 1913-1918 (2009)
84. Dayyani F, Kantarjian H, OBrien S et al. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 117(1), 110-115 (2011)
85. Abou-Jawde RM, Reed J, Kelly M et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a Phase 2 trial. Med. Oncol. 23(2), 263-272 (2006) (Pubitemid 43780310)
86. Berenson JR, Boccia R, Siegel D et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicenter, Phase II, single-arm study. Br. J. Haematol. 135(2), 174-183 (2006) (Pubitemid 44401614)
87. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. A Phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res. 13(6), 1762-1768 (2007) (Pubitemid 46952943)
88. Zheng WL, Zhang GS, Xu YX, Shen JK, Dai CW, Pei MF. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Leuk. Res. 32(2), 251-254 (2008)
89. Ardalan B, Subbarayan PR, Ramos Y et al. A Phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin. Cancer Res. 16(11), 3019-3027 (2010)
90. Bhattacharjee H, Carbrey J, Rosen BP, Mukhopadhyay R. Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem. Biophys. Res. Commun. 322(3), 836-841 (2004) (Pubitemid 39164428)
91. Leung J, Pang A, Yuen WH, Kwong YL, Tse EW. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 109(2), 740-746 (2007) (Pubitemid 46105976)
92. Zhou GB, Li G, Chen SJ, Chen Z. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta Pharmacol. Sin. 28(9), 1434-1449 (2007) (Pubitemid 47366681)
93. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract. Res. Clin. Haematol. 20(1), 57-65 (2007)
94. Fatouros DG, Ioannou PV, Antimisiaris SG. Arsonoliposomes: novel nanosizedarsenic-containing vesicles for drug delivery. J. Nanosci. Nanotechnol. 6(9-10), 2618-2637 (2006) (Pubitemid 44579935)
95. Ahn RW, Chen F, Chen H et al. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin. Cancer Res. 16(14), 3607-3617 (2010)